Biotron initiates Phase IIa clinical trial in HCV patients

Biotron claims that BIT225 is a new drug with the potential to improve treatment options for HCV patients.

The Phase IIa clinical trial is a combination study of BIT225 with the current approved treatment for HCV – interferon and ribavirin.

The trial is designed to evaluate the safety of Biotron’s drug when given daily for 28 days, as well to assess its effect on the level of virus in the blood of the patients and to see whether BIT225 can improve the efficacy of interferon and ribavirin.

In the trial, the company expects to dose around 24 infected with genotype 1 HCV twice daily with BIT225 or placebo for 28 days at the commencement of a standard course of treatment of interferon and ribavirin.